Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Good Manufacturing Practices (GMPs) from R&D through Commercialization: Fundamentals, Regulatory Trends and Best Practices


Speakers: Marion Weinreb, President, MWA Consulting, Inc.
Organizers:
Date: 2017-10-24
Time: 13:00-17:30 Pacific Time
Registration fee: (USD): Regular: $125; Academic: $75; For unemployed or students: $25; For vendor-show reps: $25; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Pacific BioLabs
Vendor show vendors registered to date: (7)BioDuro; BioKey, Inc.; Lonza; MabPlex; MilliporeSigma; Nitto Avecia Pharma Services, Inc.; PerkinElmer
Registration: http://www.PBSS.org
Registration deadline:2017-10-23  (it will close sooner if the seating cap is reached)

About the Topic

This workshop will include a discussion on the history of Good Manufacturing Practices (GMP) regulations from R&D through Commercialization, the importance of the regulations, key definitions, areas covered by the GMPs, a review of the regulations, examples of misconduct and, potential FDA actions.  After completing this workshop, participants should be able to understand the origin, purpose, and expectations of the GMP regulations.

12:45-12:55 pm

  • PBSS Welcome & Workshop Overview  
  • History of Drug Regulations
  • Basis of GMPs  

12:55-2:00 pm

  • CGMPs on a Continuum
    • Development vs Commercial Compliance
    • Review of Clinical Failures and Commercial Recalls     

2:00-2:10 pm

  • Major Sponsor Presentation      

2:10-2:25 pm

  • Break & Vendor Show                          

2:25-3:40 pm

  • Current FDA Expectations and Focus
    • Data Integrity
    • Quality Metrics
    • Quality by Design  

3:40-4:00 pm

  • Break and Vendor Show              

4:00-5:00 pm

  • Oversight of CMOs                                

5:00-5:20pm

  • Q & A

About the Speakers

Marion Weinreb has over 40 years of quality systems experience in the medical device and pharmaceutical industries. Marion has worked at major companies like Altana, Inc., Forest Laboratories, Johnson & Johnson, Syntex and Roche Bioscience. She focuses on GMP and/or QSR auditing in both non-sterile and sterile drug, device and combination systems, Pre-Approval Inspection preparation, PAI mock audits, quality systems development and continuous improvement, cGXP training, GMP document development, and problem resolution for compliance issues. She has worked for small and large companies and has a successful track record for dealing with complex compliance issues in development and commercial settings. Marion holds a BA in Biology and an MS in Pharmaceutical Marketing.  She is currently President of MWA Consulting, Inc. where provides GXP consulting expertise to MWA clients.


2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Online Workshop] Career Transition for Research Scientists
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 3/28/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad